RenovoRx Inc
Change company Symbol lookup
Select an option...
RNXT RenovoRx Inc
ARTW Art's Way Manufacturing Co Inc
ARIZU Arisz Acquisition Corp
OSH Oak Street Health Inc
LESL Leslie's Inc
AAPL Apple Inc
BYM BlackRock Municipal Income Quality Trust
DLA Delta Apparel Inc
PEG Public Service Enterprise Group Inc

Health Care : Biotechnology |
Company profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing therapies for the local treatment of solid tumors and conducting a Phase III pancreatic cancer clinical trial for its lead product candidate RenovoGem. The Company’s therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) utilizes chemotherapeutics. RenovoTAMP combines its patented delivery system, RenovoCath, with small molecule chemotherapeutic agents, which can be forced across the vessel wall using pressure, targeting these anti-cancer drugs locally to the solid tumors. Its first product candidate, RenovoGem, is a drug /device combination consisting of intra-arterial gemcitabine and RenovoCath. RenovoGem has developed for the treatment of two rare diseases: pancreatic cancer and cholangiocarcinoma (CCA). It has completed its Phase I/II and observational registry studies, with 20 and 25 patients respectively, in locally advanced pancreatic cancer (LAPC).

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low
(Above Average)

10-day average volume:

NIO Inc. ADR Falls Tuesday, Underperforms Market

5:12 pm ET December 27, 2022 (MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights.

The NIO Inc. ADR (NIO) shed 8.30% to $10.06 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.11% to 33,241.56 and the NASDAQ Composite Index falling 1.38% to 10,353.23. This was the ADR's third consecutive day of losses. NIO Inc. ADR closed $23.74 below its 52-week high ($33.80), which the company achieved on January 3rd.

Trading volume (53.8 M) remained 10.2 million below its 50-day average volume of 64.0 M.

Data source: Dow Jones Market Data, FactSet. Data compiled December 27, 2022.


(END) Dow Jones Newswires

December 27, 2022 17:12 ET (22:12 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.